Selected publications
-
Intrinsic subtype and therapeutic response among HER2-positive breast tumors from the NCCTG (Alliance) N9831 trial.
Journal of the National Cancer Institute.
2017
Academic Article
GET IT
Times cited: 14 -
Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the n9831 adjuvant trial in patients with early-stage HER2-positive breast cancer.
JAMA oncology.
2016
Academic Article
GET IT
Times cited: 91 -
Reply to P.G. Gavin et al.
Journal of Clinical Oncology.
2015
Information Resource
GET IT
Times cited: 1 -
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Breast Cancer Research.
2015
Academic Article
GET IT
Times cited: 11 -
Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.
PLoS ONE.
2015
Article
GET IT
Times cited: 4 -
A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium.
Nature Biotechnology.
2014
Academic Article
GET IT
Times cited: 388 -
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
Blood.
2012
Academic Article
GET IT
Times cited: 119